Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Propanc Biopharma, Inc.

< Previous 1 2 Next >
News headline image
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
News headline image
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
News headline image
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
News headline image
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
News headline image
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
News headline image
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
News headline image
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.